Free tool
FAERS Monitor: Hepcludex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761468 or its brand name (Hepcludex, Bulevirtide-Gmod). Reports on generic versions are filed under their own applications.
Reports
96
Serious
86
90% of reports
Hospitalization
25
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hepatic cirrhosis14
- pancytopenia10
- asthenia7
- drug ineffective7
- hepatitis d6
- virologic failure6
- fatigue5
- hepatic failure5
- hepatic fibrosis5
- thrombocytopenia5
- treatment noncompliance5
- drug-induced liver injury4
- hepatocellular carcinoma4
- lichen planus4
- off label use4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 11 |
| 2022 | 17 |
| 2023 | 12 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 35 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,063 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis dSignal | 6 | 16870.2 | 7535.6 | 78,969 |
| lichen planusSignal | 4 | 378.6 | 144.9 | 1,151 |
| hepatic fibrosisSignal | 5 | 319.7 | 136.1 | 1,284 |
| virologic failureSignal | 6 | 244.7 | 112.7 | 1,222 |
| hepatic cirrhosisSignal | 14 | 163.4 | 100.7 | 2,101 |
| hepatocellular carcinomaSignal | 4 | 115.3 | 44.2 | 346 |
| pancytopeniaSignal | 10 | 39.2 | 21.8 | 336 |
| hepatic failureSignal | 5 | 36.3 | 15.5 | 138 |
| drug-induced liver injurySignal | 4 | 27.9 | 10.7 | 79 |
| treatment noncomplianceSignal | 5 | 20.0 | 8.5 | 73 |
| thrombocytopeniaSignal | 5 | 9.8 | 4.2 | 31 |
| astheniaSignal | 7 | 4.1 | 2.0 | 14 |
| fatigue | 5 | 1.4 | 0.6 | 0 |
| drug ineffective | 7 | 1.2 | 0.6 | 0 |
| off label use | 4 | 1.0 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.